Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma
hal.structure.identifier | Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit] | |
dc.contributor.author | IMBS, Diane-Charlotte | |
hal.structure.identifier | Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit] | |
dc.contributor.author | EL CHEIKH, Raouf | |
hal.structure.identifier | Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit] | |
hal.structure.identifier | Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM] | |
dc.contributor.author | BOYER, Arnaud | |
hal.structure.identifier | Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit] | |
dc.contributor.author | CICCOLINI, Joseph | |
hal.structure.identifier | Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM] | |
dc.contributor.author | MASCAUX, Celine | |
hal.structure.identifier | Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit] | |
dc.contributor.author | LACARELLE, Bruno | |
hal.structure.identifier | Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM] | |
dc.contributor.author | BARLESI, Fabrice | |
hal.structure.identifier | Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit] | |
dc.contributor.author | BARBOLOSI, Dominique | |
hal.structure.identifier | Institut de Mathématiques de Bordeaux [IMB] | |
hal.structure.identifier | Modélisation Mathématique pour l'Oncologie [MONC] | |
dc.contributor.author | BENZEKRY, Sébastien | |
dc.date.accessioned | 2024-04-04T03:07:43Z | |
dc.date.available | 2024-04-04T03:07:43Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/193469 | |
dc.description.abstractEn | Concomitant administration of bevacizumab and pemetrexed-cisplatin is a common treatment for advanced non-squamous non-small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance drug delivery, suggesting improved efficacy with sequential administration. To investigate optimal scheduling, we conducted a study in NSCLC-bearing mice using. First, experiments demonstrated improved efficacy when using sequential versus concomitant scheduling of bevacizumab and chemotherapy. Using a mathematical model of tumor growth under therapy accounting for the normalization effect, we predicted an optimal delay of 2.8 days between bevacizumab and chemotherapy. This prediction was confirmed experimentally, with reduced tumor growth of 38% as compared to concomitant scheduling, and prolonged survival (70 vs. 74 days). Alternate sequencing of 8 days failed in achieving similar increase in efficacy, thus emphasizing the utility of modeling support to identify optimal scheduling. The model could also be a useful tool in the clinic to personally tailor regimen sequences. | |
dc.language.iso | en | |
dc.publisher | American Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics | |
dc.subject.en | Drug-drug interactions | |
dc.subject.en | Systems biology | |
dc.subject.en | Population pharmacokinetics-pharmacodynamics | |
dc.subject.en | Pharmacokinetics-pharmacodynamics | |
dc.subject.en | Combination therapy | |
dc.subject.en | Computational biology | |
dc.subject.en | Mixed effect models | |
dc.subject.en | Personalized Therapy | |
dc.subject.en | Oncology | |
dc.title.en | Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma | |
dc.type | Article de revue | |
dc.identifier.doi | 10.1002/psp4.12265 | |
dc.subject.hal | Sciences du Vivant [q-bio]/Cancer | |
dc.subject.hal | Mathématiques [math]/Systèmes dynamiques [math.DS] | |
dc.subject.hal | Sciences du Vivant [q-bio]/Bio-Informatique, Biologie Systémique [q-bio.QM] | |
dc.subject.hal | Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie | |
bordeaux.journal | CPT: Pharmacometrics and Systems Pharmacology | |
bordeaux.page | 1-9 | |
bordeaux.hal.laboratories | Institut de Mathématiques de Bordeaux (IMB) - UMR 5251 | * |
bordeaux.institution | Université de Bordeaux | |
bordeaux.institution | Bordeaux INP | |
bordeaux.institution | CNRS | |
bordeaux.peerReviewed | oui | |
hal.identifier | hal-01624423 | |
hal.version | 1 | |
hal.popular | non | |
hal.audience | Internationale | |
hal.origin.link | https://hal.archives-ouvertes.fr//hal-01624423v1 | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=CPT:%20Pharmacometrics%20and%20Systems%20Pharmacology&rft.date=2018&rft.spage=1-9&rft.epage=1-9&rft.au=IMBS,%20Diane-Charlotte&EL%20CHEIKH,%20Raouf&BOYER,%20Arnaud&CICCOLINI,%20Joseph&MASCAUX,%20Celine&rft.genre=article |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |